An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT

Hayden, Patrick; Sirait, Tiarlan; Köster, Linda; Snowden, John A.; Yakoub‐Agha, Ibrahim

doi:10.1016/j.retram.2019.05.002

Cited by 32 publications

(20 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A survey was sent to centers active in this field to solicit feedback on current approaches to the topics covered in these guidelines. 17 Their responses (41 of 50 centers) along with a literature review and assessment of both the licensing study protocols and the summaries of product characteristics (SPC) of the commercially available CAR T-cell products inform these recommendations. Finally, three teleconferences were held in preparation for a 2-day workshop that took place in Lille on 4 th -5 th April, 2019.…”

Section: Methodsmentioning

confidence: 99%

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Yakoub‐Agha

Chabannon

Bader³

et al. 2019

Haematologica

266

284

View full text Add to dashboard Cite

Ferrata Storti Foundation C himeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah TM ) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as well as relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta TM ) is approved for the treatment of relapsed/refractory high-grade B-cell lymphoma and primary mediastinal B-cell lymphoma. Both agents are genetically engineered autologous T cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient

show abstract

Section: Methodsmentioning

confidence: 99%

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Yakoub‐Agha

Chabannon

Bader³

et al. 2019

Haematologica

266

284

View full text Add to dashboard Cite

show abstract

“…Patients diagnosed with HIV infection were excluded from clinical trials [53], so data in this setting is scarce. The European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) practice recommendations have suggested that pharmaceutical companies could manufacture CAR T cells for HIV-positive patients if the viral load was undetectable after anti-retroviral treatment [54].…”

Section: Human Immunodeficiency Virus (Hiv)mentioning

confidence: 99%

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

et al. 2020

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene ciloleucel and tisagenlecleucel) have been approved for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia; many other CART constructs are in research for both hematological and non-hematological diseases. Most of the patients receiving CART therapy will develop fever at some point after infusion, mainly due to cytokine release syndrome (CRS). The onset of CRS is often indistinguishable from an infection, which makes management of these patients challenging. In addition to the lymphodepleting chemotherapy and CAR T cells, the treatment of complications with corticosteroids and/or tocilizumab increases the risk of infection in these patients. Data regarding incidence, risk factors and prevention of infections in patients receiving CART cell therapy are scarce. To assist in patient care, a multidisciplinary team from hospitals designated by the Spanish Ministry of Health to perform CART therapy prepared these recommendations. We reviewed the literature on the incidence, risk factors, and management of infections in adult and pediatric patients receiving CART cell treatment. Recommendations cover different areas: monitoring and treatment of hypogammaglobulinemia, prevention, prophylaxis, and management of bacterial, viral, and fungal infections as well as vaccination prior and after CART cell therapy.

show abstract

“…10 In this manner, this Consensus recommends that CAR-T cell treatment be performed at Centers having allogeneic or autologous BMT service already established, as in the majority of Centers in Europe and the USA. 11 BMT and/or cellular therapy accreditation is also stimulated.…”

Section: Preparation Of the Center To Perform The Clinical Use Of Car-t Cellsmentioning

confidence: 99%

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients

Clé

Hirayama

Alencar

et al. 2021

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT

Cited by 32 publications

References 12 publications

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients

Contact Info

Product

Resources

About